Form 4: SpringWorks Therapeutics Acquired by Merck KGaA in $47.00 Per Share Cash Merger

SpringWorks Therapeutics, Inc. has been acquired by Merck KGaA, Darmstadt, Germany, with all outstanding shares converted into a cash right of $47.00 per share, as detailed in a director's Form 4 filing.

Summary

• SpringWorks Therapeutics, Inc. (SWTX) has been acquired by Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Holdings Merger Sub, Inc., effective July 1, 2025.
• The merger resulted in SWTX becoming a wholly owned subsidiary of Merck KGaA.
• Each outstanding share of SWTX common stock was cancelled and converted into the right to receive $47.00 in cash, without interest and subject to tax withholding.
• Director Martin MacKay disposed of 20,023 shares of common stock (underlying restricted stock units) and 29,445 stock options as a result of the merger.
• Outstanding Restricted Stock Units (RSUs), whether vested or unvested, were converted into cash-based awards, with the cash amount equal to the Merger Consideration multiplied by the number of shares subject to the RSU.
• Outstanding stock options, whether vested or unvested, were converted into cash-based awards, with the cash amount equal to the number of shares subject to the option multiplied by the excess of the Merger Consideration ($47.00) over the option's exercise price.
• Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards will generally vest according to their original terms, with an accelerated vesting provision: 50% of each then-unvested tranche will vest on the nine-month anniversary of the closing date, subject to continued employment.
• Any outstanding option with an exercise price greater than $47.00 was cancelled for no consideration.

Sentiment

Score: 8

Explanation: The merger provides a clear, positive liquidity event for shareholders at a fixed cash price, and a structured conversion for equity award holders, which is generally favorable.

Positives

• Shareholders received a cash payout of $47.00 per share, providing liquidity and a defined return.
• Equity award holders (RSUs and options) received cash consideration for their vested awards and cash-based awards for unvested portions, with potential for accelerated vesting under continued employment.

Negatives

• SpringWorks Therapeutics, Inc. ceased to be an independent publicly traded entity.
• Stock options with an exercise price above the $47.00 merger consideration were cancelled without any payment.

Risks

• Vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards is subject to the applicable holder's continued employment with Parent through the vesting dates, including the nine-month anniversary of the closing date for accelerated vesting.

Future Outlook

SpringWorks Therapeutics, Inc. will operate as a wholly owned subsidiary of Merck KGaA. Certain unvested equity awards held by employees will convert to cash-based awards with continued vesting schedules, including a provision for 50% accelerated vesting on the nine-month anniversary of the merger closing date, contingent on continued employment.

Industry Context

This transaction represents a strategic acquisition within the biotechnology and pharmaceutical industry, where larger pharmaceutical companies often acquire smaller biotech firms to expand their pipelines and intellectual property portfolios. Such mergers provide liquidity for shareholders of the acquired company and integrate promising assets into the acquirer's operations.

Stakeholder Impact

• Shareholders: Received $47.00 per share in cash for their common stock, providing a definitive return on investment.
• Employees (with equity awards): Their outstanding RSUs and options were converted into cash-based awards, with vesting tied to continued employment, offering a retention incentive and future payouts.

Next Steps

• Vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards will continue according to their original terms.
• 50% of each then-unvested tranche of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards will vest on the nine-month anniversary of the closing date of the Merger, subject to continued employment.

Key Dates

Keywords

Merger, Acquisition, SEC Form 4, Insider Transaction, Beneficial Ownership, SpringWorks Therapeutics, Merck KGaA, SWTX, Equity Awards, Restricted Stock Units, Stock Options, Cash Merger